Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review

References

• World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Geneva: WHO Press; 2007.
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; Jul 18, 2018. Available from: https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/.
   Google Scholar
• The International Union Against Tuberculosis and Lung Disease. The global asthma report; Jul 18, 2018. Available from: https://globalasthmareport.org.
   Google Scholar
• Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005–2009. Natl Health Stat Report. 2011;32:1–14.
   PubMedGoogle Scholar
• Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35–44.
   PubMedGoogle Scholar
• Lindsay JT, Heaney LG. Nonadherence in difficult asthma – facts, myths, and a time to act. Patient Prefer Adherence. 2013;7:329–336.
   PubMed Web of Science ®Google Scholar
• Lasmar L, Camargos P, Champs NS, et al. Adherence rate to inhaled corticosteroids and their impact on asthma control. Allergy. 2009;64:784–789.
   PubMed Web of Science ®Google Scholar
• Stern L, Berman J, Lumry W, et al. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Ann Allergy Asthma Immunol. 2006;97:402–408.
   PubMed Web of Science ®Google Scholar
• Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128:1185–1191.
   PubMed Web of Science ®Google Scholar
• Marceau C, Lemiere C, Berbiche D, et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol. 2006;118:574–581.
   PubMed Web of Science ®Google Scholar
• Small M, Anderson P, Vickers A, et al. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011;28:202–212.
   PubMed Web of Science ®Google Scholar
• Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med. 2011;105:1308–1315.
   PubMed Web of Science ®Google Scholar
• Delea TE, Stanford RH, Hagiwara M, et al. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Curr Med Res Opin. 2008;24:3435–3442.
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
   Google Scholar
• Towse A, Pritchard C, Devlin N. Cost-effectiveness thresholds: economic and ethical issues. London: BSC Print Ltd. King's Fund and Office of Health Economics; 2002.
   Google Scholar
• Rosen AB, Spaulding AB, Greenberg D, et al. Patient adherence: a blind spot in cost-effectiveness analyses? Am J Manag Care. 2009;15:626–632.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. 2001;10:601–615.
   PubMed Web of Science ®Google Scholar
• Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy. 2002;59:65–94.
   PubMed Web of Science ®Google Scholar
• Hughes D, Cowell W, Koncz T, et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health. 2007;10:498–509.
   PubMed Web of Science ®Google Scholar
• Glanville J, Fleetwood K, Yellowlees A, et al. Development and testing of search filters to identify economic evaluations in MEDLINE and EMBASE. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
   Google Scholar
• Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21:240–245.
   PubMed Web of Science ®Google Scholar
• Odnoletkova I, Goderis G, Pil L, et al. Cost-effectiveness of therapeutic education to prevent the development and progression of type 2 diabetes: systematic review. J Diabetes Metab. 2014;5:438.
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049
   PubMed Web of Science ®Google Scholar
• Zafari Z, Lynd LD, Fitzgerald JM, et al. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study. J Allergy Clin Immunol. 2014;134:908.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients. J Asthma. 2016;53:538–545.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez CE, Sossa-Briceno MP , Castro-Rodriguez JA. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma. 2013;50:410–418.
   PubMed Web of Science ®Google Scholar
• Shih Y-CT, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. PharmacoEconomics. 2007;25:577–590.
   PubMed Web of Science ®Google Scholar
• Altawalbeh SM, Thorpe JM, Thorpe CT, et al. Cost-utility analysis of long-acting beta agonists versus leukotriene receptor antagonists in older adults with persistent asthma receiving concomitant inhaled corticosteroid therapy. Value Health. 2016;19:537–543.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy. 2010;65:1141–1148.
   PubMed Web of Science ®Google Scholar
• Fuhlbrigge AL, Bae SJ, Weiss ST, et al. Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density. J Allergy Clin Immunol. 2006;117:359–366.
   PubMed Web of Science ®Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118:220–225.
   PubMed Web of Science ®Google Scholar
• Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol. 2007;120:1146–1152.
   PubMed Web of Science ®Google Scholar
• Zafari Z, Sadatsafavi M, Marra CA, et al. Cost-effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma. PLoS One. 2016;11:e0146003.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez CE, Nino G, Castro-Rodriguez JA. Cost-utility analysis of daily versus intermittent inhaled corticosteroids in mild-persistent asthma. Pediatr Pulmonol. 2015;50:735–746.
   PubMed Web of Science ®Google Scholar
• Doull I, Price D, Thomas M, et al. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Curr Med Res Opin. 2007;23:1147–1159.
   PubMed Web of Science ®Google Scholar
• Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. Value Health. 2014;17:772–782.
   PubMed Web of Science ®Google Scholar
• Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17:1–342.
   PubMed Web of Science ®Google Scholar
• Doan Q, Shefrin A, Johnson D. Cost-effectiveness of metered-dose inhalers for asthma exacerbations in the pediatric emergency department. Pediatrics. 2011;127:e1105–1111.
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Risebrough N, Li C, et al. Cost-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada. Respir Med. 2014;108:1292–1302.
   PubMed Web of Science ®Google Scholar
• Gerzeli S, Rognoni C, Quaglini S, et al. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. Clin Drug Investig. 2012;32:253–265.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Cavallo M, Annoni E, et al. Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma. Expert Rev Pharmacoecon Outcomes Res. 2004;4:549–564.
   PubMedGoogle Scholar
• Simonella L, Marks G, Sanderson K, et al. Cost-effectiveness of current and optimal treatment for adult asthma. Intern Med J. 2006;36:244–250.
   PubMed Web of Science ®Google Scholar
• Bruggenjurgen B, Ezzat N, Kardos P, et al. Economic evaluation of BDP/formoterol fixed vs two single inhalers in asthma treatment. Allergy. 2010;65:1108–1115.
   PubMed Web of Science ®Google Scholar
• Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22:1765–1776.
   PubMed Web of Science ®Google Scholar
• Paggiaro P, Patel S, Nicolini G, et al. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective. Respir Med. 2013;107:1531–1537.
   PubMed Web of Science ®Google Scholar
• Stanciole AE, Ortegón M, Chisholm D, et al. Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e608
   Google Scholar
• Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245–251.
   PubMed Web of Science ®Google Scholar
• Stempel DA, Meyer JW, Stanford RH, et al. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol. 2001;107:94–98.
   PubMed Web of Science ®Google Scholar
• Bukstein DA, Henk HJ, Luskin AT. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther. 2001;23:1589–1600.
   PubMed Web of Science ®Google Scholar
• Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy. 2002;22:166–174.
   PubMed Web of Science ®Google Scholar
• Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med. 2001;95:227–234.
   PubMed Web of Science ®Google Scholar
• Jonasson G, Carlsen K, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child. 2000;83:330–333.
   PubMed Web of Science ®Google Scholar
• Mallol J, Aguirre V. Once versus twice daily budesonide metered-dose inhaler in children with mild to moderate asthma: effect on symptoms and bronchial responsiveness. Allergol Immunopathol. 2007;35:25–31.
   PubMed Web of Science ®Google Scholar
• Jentzsch NS, Camargos PA, Colosimo EA, et al. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy. 2009;64:1458–1462.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bousquet J, Busse WW, et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 2008;63:932–938.
   PubMed Web of Science ®Google Scholar
• Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114:1288–1293.
   PubMed Web of Science ®Google Scholar
• Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004;292:367–376.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Boonen A, Rabenda V, et al. The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res. 2012;12:159–166.
   PubMed Web of Science ®Google Scholar
• Strom O, Borgstrom F, Kanis JA, et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int. 2009;20:23–34.
   PubMed Web of Science ®Google Scholar
• Jonsson B, Strom O, Eisman JA, et al. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22:967–982.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics. 2011;29:895–911.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Rabenda V, Bruyere O, et al. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy. 2010;96:170–177.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Gathon HJ, Bruyere O, et al. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health. 2010;13:394–401.
   PubMed Web of Science ®Google Scholar
• Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334–336.
   PubMed Web of Science ®Google Scholar
• Slejko JF, Sullivan PW, Anderson HD, et al. Dynamic medication adherence modeling in primary prevention of cardiovascular disease: a Markov microsimulation methods application. Value Health. 2014;17:725–731.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Ethgen O, Bruyere O, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health. 2009;12:687–696.
   PubMed Web of Science ®Google Scholar
• Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging. 2007;24:37–55.
   PubMed Web of Science ®Google Scholar